Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Getting to the Bottom of the Debate 2.0 | Oligoprogressive mCRPC: Debating Local Therapy and the Sequencing of PARP Inhibitors and ¹⁷⁷Lu-PSMA-617—A Debate Between Professors Jianming Guo and Qing Zou

Treatment options for metastatic castration-resistant prostate cancer (mCRPC) are expanding rapidly. However, two major challenges remain in clinical decision-making: how to adjust treatment following oligoprogression and how to optimize the sequencing of precision therapies.